

Product Data Sheet

Product Name: Elezanumab
Cat. No.: GC69052

Chemical Properties

Cas. No. 1791416-49-3

Formula M.Wt

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets **repulsive guidance molecule A (RGMA)**. Elezanumab potently inhibited RGMA mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀ around 97 pM.

Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMA, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism^{[1][2]}.

Elezanumab (ABT-555; AE12-1Y-QL; 1-10 mg/kg; ; ; 5) Lewis ^[1]

Elezanumab (0.01, 0.1, 1, 10 mg/kg; ; ; 3) (EAE) Lewis ^[1]

Animal Model: Female Lewis rat optic neuritis models^[1]

Dosage: 1, 3, or 10 mg/kg

Administration: IV; once a week for 5 doses

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Result: Protected against the optic nerve inflammation-induced RNFL degeneration. Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg

[1]. Lili Huang, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. *Neurobiol Dis.* 2021 Nov;159:105492.

[2]. Peer B Jacobson, et al. Elezanumab, a human anti-RGMA monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates. *Neurobiol Dis.* 2021 Jul;155:105385.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA